The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Physiochemical drug properties associated with in vivo toxicological outcomes
Abstract
Relationships between physicochemical drug properties and toxicity were inferred from a data set consisting of animal in vivo toleration (IVT) studies on 245 preclinical Pfizer compounds; an increased likelihood of toxic events was found for less polar, more lipophilic compounds. This trend held across a wide range of types of toxicity and across a broad swath of chemical space.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
High lipophilicity of a drug may increase the risk of iDILI.
“High lipophilicity of a drug may increase the risk of iDILI [30].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [30]
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Flagged first, then by citations
Research works printed but not linked: 13
- Kramer, 2007, Nat. Rev. Drug Disc., 6, 636, 10.1038/nrd2378 · DOI
- Stevens, 2006, Chem. Res. Toxicol., 19, 1393, 10.1021/tx060213n · DOI
- Song, 2006, J. Chem. Inf. Model., 46, 392, 10.1021/ci050308f · DOI
- Villar, 2007, Curr. Top. Med. Chem., 7, 1509, 10.2174/156802607782194725 · DOI
- Blagg, 2006, Ann. Rep. Med. Chem., 41, 353
- Robichaud, 2001, Neuropharmacology, 40, 262, 10.1016/S0028-3908(00)00142-8 · DOI
- Smith, 2005, Curr. Opin. Investig. Drugs, 6, 1136
- Krejsa, 2003, Curr. Opin. Drug Discov. Dev., 6, 470
- Kalgutkar, 2005, Expert Opin. Drug Metab. Toxicol., 1, 91, 10.1517/17425255.1.1.91 · DOI
- Kalgutkar, 2005, Curr. Drug Metab., 6, 161, 10.2174/1389200054021799 · DOI
- Ertl, 2000, J. Med. Chem., 43, 371, 10.1021/jm000942e · DOI
- Gleeson, 2007, J. Med. Chem., 50, 101, 10.1021/jm060981b · DOI
- Azzaoui, 2007, ChemMedChem, 2, 874, 10.1002/cmdc.200700036 · DOI
Cited by
Sorted by citations
An analysis of the attrition of drug candidates from four major pharmaceutical companies
Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., et al. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4609 · Cited by 1,450
EASL Clinical Practice Guidelines: Drug-induced liver injury
Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.014 · Cited by 1,276
The role of ligand efficiency metrics in drug discovery
Hopkins, A. L., Keserü, G. M., Leeson, P. D., Rees, D. C., & Reynolds, C. H. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4163 · Cited by 1,181
Automated design of ligands to polypharmacological profiles
Besnard, J., Ruda, G. F., Setola, V., Abecassis, K., Rodriguiz, R. M., Huang, X.-P., Norval, S., Sassano, M. F., Shin, A. I., Webster, L. A., et al. (2012) · Nature · doi:10.1038/nature11691 · Cited by 832
Reducing safety-related drug attrition: the use of in vitro pharmacological profiling
Bowes, J., Brown, A. J., Hamon, J., Jarolimek, W., Sridhar, A., Waldron, G., & Whitebread, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3845 · Cited by 748
Central nervous system multiparameter optimization desirability: Application in drug discovery
Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00029 · Cited by 653
Self-citationTargeted Covalent Inhibitors for Drug Design
Baillie, T. A. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201601091 · Cited by 578
50 years of oral lipid-based formulations: provenance, progress and future perspectives
Feeney, O. M., Crum, M. F., McEvoy, C. L., Trevaskis, N. L., Williams, H. D., Pouton, C. W., Charman, W. N., Bergström, C. A. S., & Porter, C. J. H. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.007 · Cited by 426
Holzer, P., Masuya, K., Furet, P., Kallen, J., Valat-Stachyra, T., Ferretti, S., Berghausen, J., Bouisset-Leonard, M., Buschmann, N., Pissot-Soldermann, C., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00810 · Cited by 203
Labbé, C. M., Laconde, G., Kuenemann, M. A., Villoutreix, B. O., & Sperandio, O. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.05.003 · Cited by 104
Bhattacharya, S. K., Andrews, K., Beveridge, R., Cameron, K. O., Chen, C., Dunn, M., Fernando, D., Gao, H., Hepworth, D., Jackson, V. M., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400473x · Cited by 73
Self-citationChinese guideline for the diagnosis and treatment of drug-induced liver injury: an update
Mao, Y., Ma, S., Liu, C., Liu, X., Su, M., Li, D., Li, Y., Chen, G., Chen, J., Chen, J., et al. (2024) · Hepatology International · doi:10.1007/s12072-023-10633-7 · Cited by 62
A structural analysis of the FDA green book-approved veterinary drugs and roles in human medicine
Scott, K. A., Qureshi, M. H., Cox, P. B., Marshall, C. M., Bellaire, B. C., Wilcox, M., Stuart, B. A. R., & Njardarson, J. T. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01502 · Cited by 56
How do metabolites differ from their parent molecules and how are they excreted?
Kirchmair, J., Howlett, A., Peironcely, J. E., Murrell, D. S., Williamson, M. J., Adams, S. E., Hankemeier, T., van Buren, L., Duchateau, G., Klaffke, W., et al. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci300487z · Cited by 43
Focused Libraries for Epigenetic Drug Discovery: The Importance of Isosteres: Miniperspective
Green, A. I., & Burslem, G. M. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00592 · Cited by 21
Wright, P. S. R., Briggs, K. A., Thomas, R., Smith, G. F., Maglennon, G., Mikulskis, P., Chapman, M., Greene, N., Phillips, B. U., & Bender, A. (2023) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2022.105308 · Cited by 8
Self-citationDrug‐Induced Hepatotoxicity: Advances in Preclinical Predictive Strategies and Tools
Dambach, D. M. (2014) · Predictive ADMET · doi:10.1002/9781118783344.ch19 · Cited by 4
Metadata
- Authors
- Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., Greene, N., Huang, E., Krieger-Burke, T., Loesel, J., Wager, T., Whiteley, L., & Zhang, Y.
- Venue
- Bioorganic & Medicinal Chemistry Letters
- Publisher
- Elsevier BV
- Published
- 2008-09
- Volume
- 18
- Issue
- 17
- Pages
- 4872-4875
- ISSN
- 0960-894X
- Cited by
- 946
- References
- 2
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review